PN-477 is one of the most anticipated metabolic therapies in development. With its triple agonist action and massive weight loss potential, researchers, investors, and patients alike are watching closely. Here are the latest updates on its timeline, trials, and upcoming milestones.
📅 July 2025 – Preclinical Development Concludes
Protagonist Therapeutics has wrapped up key preclinical studies, showing strong efficacy and tolerability in rodent and primate models. Final safety profiling is being completed in preparation for FDA submission.
🧪 Q4 2025 – IND Filing (Investigational New Drug)
The company is expected to file for an IND by the end of 2025, which would open the door for Phase 1 clinical trials in humans. This step is required before any new compound can be tested in people.
🧬 Early 2026 – Phase 1 Trials Begin
Initial human trials will focus on dosing, tolerability, and pharmacokinetics. While weight loss won’t be the primary goal, researchers will begin collecting metabolic and safety data.
🌍 Global Expansion Plans
While the U.S. will lead the early phases, Protagonist is rumored to be preparing regulatory pathways in the EU and Australia for future multi-center studies.
📣 PN-477 Community Announcements
- Discord community launched – connect with others tracking PN-477
- Research roundup blog section coming soon
- Newsletter sign-up launching August 2025
🗓 Long-Term Forecast
- 2026: Phase 1 human trials (safety)
- 2027–2028: Phase 2 trials (obesity, diabetes, NASH)
- 2029: NDA filing if successful
- 2030: Market launch possible
📢 Stay Connected
We’ll keep this page updated as official announcements are released. Bookmark this page or join the PN-477 Discord for live alerts, documents, and research analysis.